AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01372995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive substance
Description: Inactive substance given enterally for 5 days.
Study NCT04696822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Nasal Product, 1.6 mg
Description: Single dose Nasal powder spray without allergen challenge
Study NCT04696822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine nasal product, 1.6 mg + allergen
Description: Single dose Nasal powder spray with allergen challenge
Study NCT04696822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Injection 0.3 mg
Description: Intramuscular injection
Study NCT04696822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Nasal Product, 3.2 mg
Description: Twice dose Nasal powder spray without allergen challenge
Study NCT04696822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Nasal Product, 3.2 mg + allergen
Description: Twice dose Nasal powder spray with allergen challenge
Study NCT01580670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650
Description: TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Week 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
Study NCT04183296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
Study NCT04183296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
Study NCT01653821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid body excision
Study NCT03971136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pulmonary ultrasound
Description: The subjects will have an ultrasound on admission and on day 1, 2 and 3
Study NCT01576679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cathflo (Alteplase)
Study NCT01576679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02764762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion.
Study NCT02764762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab injection for subcutaneous use.
Study NCT02764762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate oral tablets.
Study NCT01231451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPA
Description: All subjects will take DMPA
Study NCT04181892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap + connective tissue graft
Description: connective tissue graft covered by a coronally advanced flap with connective tissue graft apical of the cementoenamel junction level
Study NCT00602641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT00602641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT00602641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT00602641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Given PO
Study NCT00602641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given PO
Study NCT00602641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT00602641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT00602641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00602641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Given PO
Study NCT01097538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body-weight supported treadmill training
Description: Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
Study NCT01097538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total body recumbent stepper training
Description: Patients will train using the Nustep T4 (TRS 4000) which is a recumbent cross trainer that provides a full body workout in a seated position. The Nustep trainer allows patients to achieve a natural stepping motion against graded loads with bilateral reciprocal movement of the arms. Recumbent training is safe and easily accessible for patients of all ability levels with a swivel chair to aid in patient transfers. Foot straps, leg stabilizers and hand stabilizers may be used for added control and proper body alignment.
Study NCT02043210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment as Usual
Description: Treatment normally offered at this clinic which could include individual or group substance use counseling sessions one time per week lasting one hour each time.
Study NCT02043210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT plus Standard treatment as usual
Description: Subjects work with a computerized program in Spanish that teaches skills for stopping substance use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus Standard treatment as usual
Study NCT02468427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hands-on teaching
Description: Training session of 30 minutes duration with every proband performing a vacuum extraction on a pelvic training model.
Study NCT00991133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine incorporated into a 5-drug regimen
Description: Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
Study NCT00083122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00083122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00083122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/flavopiridol
Description: Given IV
Study NCT01889771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: nicoderm patches are distributed in two different supplies through a telephone quitline
Study NCT01552642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: face-to-face meetings and access to a website
Description: The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
Study NCT04181892 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronally advanced flap + connective tissue graft
Description: connective tissue graft covered by a coronally advanced flap with connective tissue graft apical of the cementoenamel junction level
Study NCT01977755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danegaptide
Study NCT02468427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frontal teaching
Description: Training session of 30 minutes duration consisting of a video which demonstrates how to perform a vacuum extraction on a pelvic training model.
Study NCT02293629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986147
Study NCT02293629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-986147
Study NCT02293629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-986147
Study NCT02293629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching BMS-986147
Study NCT00297154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification (diet, exercise, and behavior)
Description: Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
Study NCT06580808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fontan Training Group
Description: The Fonta training group consisted of 14 children in the late postoperative period of Fontan surgery. These children underwent cardiopulmonary testing, spirometry, chest ultrasound to assess the diaphragm, 6-minute walk test, respiratory muscle strength and quality of life. These tests were performed at the initial stage and after two months of inspiratory muscle training to assess the results of these in postoperative patients and what changes the training could bring. The training was performed with the Power Breath device, the carda was quantified at 40% of the force exerted at maximum inspiratory pressure by manovacuometry. The patient was asked to perform 3 sets of 20 repetitions twice over the course of 7 days of the week. Monitoring was done in person and virtually, and the carda was increased according to the evaluator's perception of the ease of the exercise or if the patient reported it to be easy. The training lasted 2 months.
Study NCT01977755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04632186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXOPULSE Mollii suit
Description: All sessions start with rated perceived pain with the NRS and the ShoulderQ questionnaire and assessed body function with the Fugl-Meyer UE scale, Ashworth scale and the Neuroflexor, before the start of the intervention.~Session 1. Stimulation with TENS according to best clinical practice. Session 2. Stimulation with the Mollii suit according to current best experienced practice with selective stimulation directed to the shoulder region Session 3. Stimulation using the full body Mollii suit according to current best experienced practice.~Outcome of each session is assessed with a pain drawing, the NRS (during and after treatment) and the Fugl-Meyer UE, Ashworth scale and the Neuroflexor (after treatment).
Study NCT00223041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvastatin
Description: Arm A receives fluvastatin Arm b receives no fluvastatin
Study NCT06265103 — intervention group
Intervention type: OTHER
Intervention: Clinical care and quality improvement
Description: All eligible patients at each center will be included in the registry for clinical care, quality improvement and other activities that do not meet the regulatory requirements of human subjects research. Use of data for these purposes is not considered to be a human subjects research activity and will be covered under a Business Associates Agreement and a Participation and Data Use Agreement.
Study NCT01842139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: basiliximab
Description: Given IV
Study NCT01842139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1 126-134 peptide vaccine
Description: Given SC
Study NCT01842139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC
Study NCT01842139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly ICLC
Description: Given SC
Study NCT01842139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04452708 — intervention group
Intervention type: DEVICE
Intervention: HFNC
Description: HFNV vs NIV vs conventional nasal cannula
Study NCT01792011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVI-guided fluid management
Description: In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).
Study NCT03214913 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early Goal Directed Therapy
Description: EGDT therapy ：30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenine，red blood cell transfusion if necessary.
Study NCT03214913 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ruijin Strategy
Description: Ruijin Strategy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%\~35%.
Study NCT02745431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT02745431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01861223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)
Study NCT05496270 — intervention group
Intervention type: PROCEDURE
Intervention: total mesorectal excision
Study NCT03313557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wee-1 kinase inhibitor AZD1775
Description: Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.
Study NCT01843699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate flexible dosage
Study NCT01843699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching tablets
Study NCT03204994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Fluorescence guided lymphatic mapping using indocyanine green.
Study NCT00655408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: elemental iron
Description: Iron supplementation.
Study NCT04858646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental( Group A ): Aerobic exercises
Description: Subjects in A group was treated with different types of aerobic exercises such as 10 minute walking, 10 minute trampoline exercise and 10 minutes ball throwing activities
Study NCT04858646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional( Group B): Conventional Physical therapy
Description: The group B was treated with conventional therapy. Conventional treatment protocol passive ROM and stretching passive ROM for 15 minutes and stretching for 15 minutes.Treatment duration for both groups will be 30 minutes. Each subject received total30sessions of the treatment, with 5 treatment sessions per week for 6 weeks
Study NCT02208193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and psycho-behavioral effects of an artistic dimension
Study NCT02975167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient Cervical Ripening
Description: The experimental arm of the study will be subjects randomized to the outpatient group. Once randomized, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with outpatient induction of labor. Following placement of the Foley catheter, the subjects will be given detailed instructions for which to return to the hospital, as well as provided a 24 hour phone number to call if they have questions. They will be instructed to return to the hospital once the catheter falls out or if 24 hours has passed since its placement. Upon returning to the hospital, subjects will complete another survey assessing their satisfaction with their induction process.
Study NCT02975167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inpatient Cervical Ripening
Description: Once randomized to this group, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with inpatient induction of labor. Following placement of the Foley catheter, the subjects will undergo normal labor monitoring until their Foley catheter either falls out or is removed at 24 hours. At this time subjects will complete another survey assessing their satisfaction with their induction process.
Study NCT02975167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foley catheter placement
Description: Subjects randomized to both the inpatient and the outpatient arms will receive this intervention following completion of a survey. A Bard(TM) 16G two-way 5cc silicone-coated latex Foley catheter will be placed by a physician-member of the research team using a sterile metal speculum and ring forceps, or by hand, depending on physician preference. Once placed within the cervical canal, the Foley will be filled with 60cc of saline
Study NCT02975167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Foley Questionnaire
Description: Prior to randomization into inpatient or outpatient arms, all subjects will complete a questionnaire assessing their attitudes, opinions, fears and anxiety regarding induction of labor.
Study NCT02975167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-Foley Questionnaire
Description: Following removal of the Foley catheter (either by a physician at 24 hours or spontaneously), all subjects will complete the same questionnaire as prior assessing their attitudes, opinions, fears and anxiety regarding their induction of labor.
Study NCT02975167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal Non-Stress Test
Description: Following placement of the Foley catheter, all subjects, regardless of arm they are randomized to, will undergo a 20-minute NST. The NST will be read by a physician-member of the research team. If the NST is considered to be suspicious based on the physician's evaluation, subjects randomized to the outpatient arm will be moved to the inpatient arm, but evaluated as part of the outpatient arm on an intent-to-treat basis. All subjects randomized to the inpatient arm will be placed on continuous fetal heart rate monitoring, regardless of physician evaluation of the NST.
Study NCT01613248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1602
Description: Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
Study NCT01613248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching MK-1602
Description: Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
Study NCT01613248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded.
Study NCT01613248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded.
Study NCT01491854 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bloodsampling
Description: Bloodsampling
Study NCT03404128 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery
Study NCT02571504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plasticity-based Adaptive Cognitive Remediation (PACR)
Description: Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)